Haemonetics Corporation (HAE)vsStryker Corporation (SYK)
HAE
Haemonetics Corporation
$71.28
+2.05%
HEALTHCARE · Cap: $3.55B
SYK
Stryker Corporation
$305.66
+2.21%
HEALTHCARE · Cap: $119.69B
Smart Verdict
WallStSmart Research — data-driven comparison
Stryker Corporation generates 1794% more annual revenue ($25.27B vs $1.33B). SYK leads profitability with a 13.2% profit margin vs 7.3%. HAE appears more attractively valued with a PEG of 1.25. SYK earns a higher WallStSmart Score of 57/100 (C).
HAE
Buy56
out of 100
Grade: C
SYK
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+33.9%
Fair Value
$86.95
Current Price
$71.28
$15.67 discount
Margin of Safety
-39.3%
Fair Value
$223.02
Current Price
$305.66
$82.64 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 28.4% YoY
Large-cap with strong market position
Areas to Watch
Premium valuation, high expectations priced in
4.8% revenue growth
Distress zone — elevated risk
7.3% margin — thin
Premium valuation, high expectations priced in
2.6% revenue growth
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : HAE
The strongest argument for HAE centers on EPS Growth. PEG of 1.25 suggests the stock is reasonably priced for its growth.
Bull Case : SYK
The strongest argument for SYK centers on Market Cap. PEG of 1.47 suggests the stock is reasonably priced for its growth.
Bear Case : HAE
The primary concerns for HAE are P/E Ratio, Revenue Growth, Altman Z-Score. Debt-to-equity of 1.54 is elevated, increasing financial risk.
Bear Case : SYK
The primary concerns for SYK are P/E Ratio, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
SYK carries more volatility with a beta of 0.79 — expect wider price swings.
HAE is growing revenue faster at 4.8% — sustainability is the question.
SYK generates stronger free cash flow (415M), providing more financial flexibility.
Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
SYK scores higher overall (57/100 vs 56/100). HAE offers better value entry with a 33.9% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Haemonetics Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Haemonetics Corporation, a healthcare company, offers medical products and solutions. The company is headquartered in Boston, Massachusetts.
Visit Website →Stryker Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?